Beta Drugs reported a 41% year-on-year rise in consolidated net profit to ₹165 Mn for the quarter ended June 30, 2026, driven by robust growth in its branded oncology and contract manufacturing segments. The specialty pharmaceutical company recorded revenue from operations of ₹1,255 Mn, a 25.2% increase from ₹1,002 Mn in the corresponding quarter of the previous fiscal year. The improvement in profitability was supported by a favorable shift in product mix towards higher-margin branded businesses and reduced finance costs following the conversion of Compulsorily Convertible Debentures (CCDs).

The Board of Directors approved the unaudited standalone and consolidated financial results for Q1FY27 at a meeting held on July 20, 2026. The results were reviewed by the Audit Committee and are subject to a limited review by the statutory auditor, Khurana Sharma & Company. Beta Drugs reiterated its guidance for 20-25% consolidated revenue growth for FY27, aiming to derive over 50% of total turnover from own branded products by 2030.

Segmental Performance

The branded oncology business delivered stellar performance, growing 47% year-on-year to record sales of ₹330 Mn. This growth was attributed to improved performance from existing products and increasing acceptance of new launches. The contract manufacturing (CMO) business grew by 41% year-on-year, supported by strong traction with customers and new launches, including proprietary Novel Drug Delivery System (NDDS) products. The exports business recorded ₹172 Mn in sales, while the Nivian segment, acquired in April 2026, grew by 45% year-on-year due to increased penetration and full-quarter performance of new products launched in Q4FY26.

Financial Metrics

Consolidated EBITDA stood at ₹274 Mn, representing a 39.1% increase from ₹197 Mn in Q1FY26. EBITDA margins expanded by 217 basis points to 21.83% from 19.66%. Gross margin improved to 56.6% compared to 50.4% in Q1FY26, reflecting the favorable shift toward higher-margin branded and export businesses. Net profit after tax (PAT) rose to ₹165 Mn from ₹117 Mn, with PAT margins expanding by 147 basis points to 13.15%.

The reduction in finance costs contributed significantly to the bottom-line improvement. Interest cost associated with CCDs was ₹26 Mn for Q1FY27 compared to ₹33 Mn in Q1FY26. Other income declined by 48.3% to ₹15 Mn from ₹29 Mn in the previous year.

Strategic Outlook

Beta Drugs is diversifying beyond oncology with strategic expansions into dermatology and IVF through the acquisition of Nivian Lifesciences Pvt. Ltd. The company holds a 66.09% stake in Nivian, consolidating its IVF revenues from FY27 onwards. With manufacturing capacity utilization at 67.30% for Adley Formulations and 79.42% for Beta Drugs Ltd India Formulation, the company is well-positioned to capitalize on rising demand. Backward integration in Key Starting Materials (KSMs) and advanced intermediates is expected to further improve operating margins.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE351Y01019/65fc2e6eb9c64497.pdf

Beta Drugs Limited announced the completion of its acquisition of 66.09% equity shares in Nivian Lifesciences Private Limited. The transaction involved the transfer of 10,94,535 equity shares, with 64.26% transferred on or before 30th April, 2026, and the remaining shares transferred on 22nd May, 2026. Consequently, Nivian Lifesciences Private Limited became a subsidiary of the company in April.

Acquisition Details

The acquisition was executed under a share swap arrangement. Following the completion, the company will initiate the process for listing approval with the National Stock Exchange of India (NSE) and execute the electronic credit of shares through corporate action. The intimation was submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Context

The company had previously reported total consolidated revenues of Rs 396.0 crores for FY26, a 7.4% increase from Rs 368.8 crores in FY25. The acquisition of Nivian Lifesciences is part of the company's strategic roadmap, "Beta Vision 2030", targeting a revenue mix shift towards branded formulations and exports. Nivian reported revenues of INR 45-46 crores for FY26 with EBITDA margins of 18%-19%.